obesity drug news today glp-1 september 29 2025 New oral drugs could offer more options for weight loss Obesity GLP-1 Market Size to

TripleHormone-Receptor Agonist Retatrutide for Obesity a Phase 2 Trial

Resmetirom: acts on the MASH and fibrosis regression by intrahepatic path Resmetirom is an orally administered, liver-targeted thyroid hormone receptor- (THR) selective agonist

Fundamentally, GPL-1 drugs work by reducing appetite and cravings and, in turn, reducing the number of calories that people are consuming

[(accessed on 15 November 2021)]

If youre considering compounded GLP-1s, make sure theyre true FDA-approved formulationsnot unstudied salt versions

Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia Donghee Kang 1 , Dughyun Choi 2 Received August 8, 2025